Randomized Phase II 2 X 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose Dense AC in Hormone Receptor-poor/HER2-Negative Resectable Breast Cancer

CALGB/Alliance 40603: Long-term outcomes after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer (TNBC)

J Shepherd;K Ballman;M-Y Polley;J Campbell;C Fan;S Selitsky;A Fernandez-Martinez;J Parker;K Hoadley;Z Hu;Y Li;M Soloway;P Spears;B Singh;S Tolaney;G Somlo;E Port;C Ma;C Kuzma;E Mamounas;M Golshan;J Bellon;D Collyar;O Hahn;C Hudis;E Winer;A Partridge;T Hyslop;L Carey;C Perou;W Sikov Journal of Clinical Oncology Jan 19;JCO2101506. doi: 10.1200/JCO.21.01506. Online ahead of print

PMid: PMID35044810

CALGB/Alliance 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) (+/- carboplatin (Cb) and bevacizumab (Bev)) in triple-negative breast cancer (TNBC)

W Sikov;M-Y Polley;E Twohy;C Perou;B Singh;DA Berry;S Tolaney;G Somlo;E Port;R Qamar;K Sturtz;E Mamounas;M Golshan;J Bellon;D Collyar;O Hahn;C Hudis;E Winer;A Partridge;L Carey J Clin Oncol 37(suppl; abstr 591); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster session

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II-III triple-negative breast cancer: CALGB 40603 (Alliance)

WM Sikov;DA Berry;CM Perou;B Singh;CT Cirrincione;SM Tolaney;CS Kuzma;TJ Pluard;G Somlo;ER Port;M Golshan;JR Bellon;D Collyar;OM Hahn;LA Carey;C Hudis;E Winer Journal of Clinical Oncology 33(1):13-21

PMid: PMID25092775 | PMC number: PMC4268249

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclictaxel followed by doxorubicin and cyclophasphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance)

M Golshan;CT Cirrincione;DA Berry;W Sikov;S Jaskinski;G Somlo;E Winer;C Hudis;D Ollila American Surgical Association (April 23-25, 2015, San Diego, CA), oral presentation, abst. 3;

Impact of neoadjuvant therapy on breast conservation rates in triple- negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance)

M Golshan;C Cirrincione;D Berry;L Carey;W Sikov;N Henry;G Somlo;E Port;E Winer;C Hudis;D Ollila Journal of Clinical Oncology 33:5s (suppl; abstr 1007); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance)

M Golshan;CT Cirrincione;W Sikov;DA Berry;S Jasinski;TF Weisberg;G Somlo;C Hudis;E Winer;D Ollila Annals of Surgery Sep;262(3):434-439

PMid: PMID26222764

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)

W Sikov;DA Berry;C Perou;B Singh;C Cirrincione;S Tolaney;G Somlo;E Port;R Qamar;K Sturtz;E Mamounas;M Golshan;J Bellon;D Collyar;O Hahn;L Carey;C Hudis;E Winer San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), oral, abst. S2-05;

Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates with neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev) in triple-negative breast cancer (TNBC):correlative studies from CALGB 40603/CALGB 150709 (Alliance).

W Sikov;W Barry;A Hoadley;BN Pitcher;B Singh;S Tolaney;C Kuzma;T Pluard;G Somlo;E Port;M Golshan;DA Berry;O Hahn;L Carey;C Perou;C Hudis;E Winer San Antonio Breast Cancer Symposium Annual Meeting (December 9-13, 2014, San Antonio, TX), abstr. [S4-05], oral presentation;